Mirum Pharmaceuticals Files 8-K/A Amendment
Ticker: MIRM · Form: 8-K/A · Filed: 2026-04-08T16:13:55-04:00
Sentiment: neutral
Topics: amendment, exhibits, financial-statements
TL;DR
Mirum Pharma filed an 8-K/A amendment on 4/8/26, adding exhibits and financial statement info.
AI Summary
Mirum Pharmaceuticals, Inc. filed an amendment (8-K/A) on April 8, 2026, to its previously filed report. This amendment primarily concerns Item 9.01, which relates to Financial Statements and Exhibits. The filing includes updated or additional exhibits, such as EX-23.1, EX-99.1, and EX-99.2, alongside the iXBRL formatted 8-K/A document.
Why It Matters
This amendment indicates a procedural update or addition of required documentation to a previous filing, potentially related to financial reporting or corporate events.
Risk Assessment
Risk Level: low — This filing is an amendment to a previous report, primarily containing exhibits and financial statement information, which typically does not represent new material risks.
Key Numbers
- 0001759425-26-000021 — SEC Accession Number (Unique identifier for this specific filing)
Key Players & Entities
- Mirum Pharmaceuticals, Inc. (company) — Filer of the 8-K/A amendment
- 0001759425 (company) — CIK number for Mirum Pharmaceuticals, Inc.
- 2026-04-08 (date) — Filing date of the 8-K/A amendment
- 2026-01-23 (date) — Period of report for the filing
FAQ
What specific financial statements or exhibits were added or amended in this 8-K/A filing?
The filing includes exhibits EX-23.1, EX-99.1, and EX-99.2, along with the iXBRL formatted 8-K/A document, suggesting these are the primary additions or amendments.
What is the purpose of an 8-K/A filing?
An 8-K/A filing is an amendment to a previously filed 8-K report, used to correct or supplement information previously disclosed.
When was the original report that this 8-K/A amends likely filed?
While not explicitly stated, the 'Period of Report' is 2026-01-23, and the amendment was filed on 2026-04-08, suggesting the original report was filed around or before January 23, 2026.
What is Mirum Pharmaceuticals, Inc.'s primary business according to the filing details?
The SIC code 2834 indicates the company is in Pharmaceutical Preparations.
Where is Mirum Pharmaceuticals, Inc. located?
The company's mailing and business address is 989 EAST HILLSDALE BOULEVARD, SUITE 300, FOSTER CITY, CA 94404.
From the Filing
EDGAR Filing Documents for 0001759425-26-000021 This page uses Javascript. Your browser either doesn't support Javascript or you have it turned off. To see this page as it is meant to appear please use a Javascript enabled browser. SEC.gov EDGAR Latest Filings Filings search tools Filing Detail SEC Home » Company Search » Current Page Form 8-K/A - Current report: [Amend] SEC Accession No. 0001759425-26-000021 Filing Date 2026-04-08 Accepted 2026-04-08 16:13:55 Documents 14 Period of Report 2026-01-23 Items Item 9.01: Financial Statements and Exhibits Interactive Data Document Format Files Seq Description Document Type Size 1 8-K/A mirm-20260123.htm iXBRL 8-K/A 31932 2 EX-23.1 mirm-20260408xex231.htm EX-23.1 2485 3 EX-99.1 mirm-20260408xex991.htm EX-99.1 415994 4 EX-99.2 mirm-20260408xex992.htm EX-99.2 198918 Complete submission text file 0001759425-26-000021.txt 831499 Data Files Seq Description Document Type Size 5 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT mirm-20260123.xsd EX-101.SCH 1782 6 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT mirm-20260123_lab.xml EX-101.LAB 21885 7 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT mirm-20260123_pre.xml EX-101.PRE 12508 18 EXTRACTED XBRL INSTANCE DOCUMENT mirm-20260123_htm.xml XML 2876 Mailing Address 989 EAST HILLSDALE BOULEVARD, SUITE 300 FOSTER CITY CA 94404 Business Address 989 EAST HILLSDALE BOULEVARD, SUITE 300 FOSTER CITY CA 94404 650-667-4085 Mirum Pharmaceuticals, Inc. (Filer) CIK : 0001759425 (see all company filings) EIN. : 831281555 | State of Incorp.: DE | Fiscal Year End: 1231 Type: 8-K/A | Act: 34 | File No.: 001-38981 | Film No.: 26848275 SIC : 2834 Pharmaceutical Preparations (CF Office: 03 Life Sciences)